Melanoma Diagnostics and Therapeutics Market Forecasts to 2030 - Global Analysis By Cancer Type, By Diagnosis (Dermatoscopy, Blood Tests, Computed Tomography Scan and Other Diagnosis), Therapy, Application and By Geography

According to Stratistics MRC, the Global Melanoma Diagnostics and Therapeutics Market is growing at a CAGR of 17.1% during the forecast period. Melanoma diagnostics involve the identification and assessment of melanocytic lesions to diagnose skin cancer. Techniques include dermoscopy, biopsy, and molecular testing to analyze genetic mutations. Therapeutics for melanoma comprise surgical excision, immunotherapy, targeted therapy, and chemotherapy. Immunotherapies like checkpoint inhibitors and targeted therapies addressing specific genetic alterations play a crucial role. Early detection and personalized treatment strategies are pivotal in managing melanoma.

According to the American Cancer Society, about 99,780 new melanomas will be diagnosed in the United States in 2022, and around 7,650 people are expected to die of melanoma in the same year.

Market Dynamics:

Driver:

Rising incidence of melanoma

Factors such as prolonged sun exposure, changing lifestyles, and genetic predispositions contribute to a rising number of melanoma cases globally. This surge in incidence necessitates advanced diagnostic tools and therapeutic interventions. Increased awareness campaigns and routine skin screenings further amplify the demand for early detection and effective treatments. The industry's response to this growing health concern involves continuous innovation in diagnostics and therapeutics, positioning the rising incidence of melanoma as a crucial driver fueling market expansion.

Restraint:

High treatment costs

The expenses associated with innovative diagnostics, targeted therapies, and immunotherapies for melanoma can be substantial, limiting accessibility for a portion of the patient population. This financial barrier hampers timely and optimal treatment, potentially impacting patient outcomes. Additionally, high costs may strain healthcare systems and result in economic challenges for both individuals and payers, impacting overall market growth.

Opportunity:

Advancements in diagnostic technologies

Innovative diagnostic tools, such as high-resolution imaging techniques, liquid biopsy assays, and molecular profiling, enable earlier and more accurate detection of melanoma. The enhanced sensitivity and specificity of these technologies contribute to timely interventions, improving patient outcomes. Moreover, non-invasive and precise diagnostic methods align with the growing trend of personalized medicine, facilitating tailored treatment approaches. These technological advancements not only aid in early diagnosis but also play a crucial role in monitoring treatment response and disease progression.

Threat:

Limited availability of specialized healthcare centers

The limited availability of specialized healthcare centers represents a significant threat to the melanoma diagnostics and therapeutics market. Melanoma often requires specialized expertise for accurate diagnosis and tailored treatment plans. The scarcity of such centers can lead to delays in diagnosis, hinder access to advanced therapeutic interventions, and limit patient outcomes. Additionally, patients may face geographical barriers, particularly in underserved regions, impacting timely access to crucial diagnostic services and cutting-edge therapies, which limits market expansion.

COVID-19 Impact:

The COVID-19 pandemic significantly impacted the melanoma diagnostics and therapeutics market. Disruptions in healthcare services, reprioritization of resources, and patients' concerns about visiting healthcare facilities led to delays in melanoma diagnosis and treatment. However, the pandemic underscored the importance of innovative and remote healthcare solutions, accelerating the adoption of telemedicine and digital health technologies.

The blood tests segment is expected to be the largest during the forecast period

The blood testing segment is expected to be the largest in the melanoma diagnostics market due to its non-invasive nature and efficiency in detecting biomarkers associated with melanoma. Blood-based tests offer a convenient and accessible means for early detection, enabling timely intervention. Advancements in liquid biopsy technologies and the identification of circulating tumor markers in blood contribute to the segment's prominence. As the demand for accurate, less invasive diagnostic methods grows, the blood testing segment is anticipated to dominate, catering to the increasing need for effective melanoma detection and monitoring.

The radiotherapy segment is expected to have the highest CAGR during the forecast period

The radiotherapy segment is projected to achieve lucrative growth in the melanoma diagnostics and therapeutics market. This growth is attributed to the increasing adoption of radiotherapy as an effective treatment option for melanoma. Technological advancements in radiotherapy techniques, including intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery, contribute to enhanced precision and reduced side effects. The growing emphasis on combination therapies, where radiotherapy is integrated into comprehensive treatment strategies, further propels the demand for radiotherapy.

Region with largest share:

North America is poised to command the largest market share in the melanoma diagnostics and therapeutics market due to its advanced healthcare infrastructure, a high prevalence of melanoma cases, and robust research and development activities. Moreover, increasing awareness, early adoption of innovative diagnostic technologies, and the presence of key market players contribute to North America's dominant position. Additionally, favorable reimbursement policies, a proactive regulatory environment, and a focus on personalized medicine further drive the region's leadership in the market.

Region with highest CAGR:

The Asia Pacific region is poised to experience the highest growth rate in the melanoma diagnostics and therapeutics market due to increasing awareness, improving healthcare infrastructure, rising disposable income, and a growing aging population that contribute to a higher prevalence of melanoma cases. Additionally, advancements in healthcare technologies, expanding research initiatives, and a focus on personalized medicine in key economies within the region further drive the demand for advanced diagnostics and therapeutics.

Key players in the market:

Some of the key players in Melanoma Diagnostics And Therapeutics Market include Abbott Diagnostics, Agilent Technologies, Amgen, Inc., AstraZeneca, Biomerieux SA, Bristol Myers Squibb, Caliber Imaging & Diagnostics, Inc., Canfield Scientific, Inc., Dermlite, DermTech, Eli Lilly and Company, Roche Holding AG, GlaxoSmithKline PLC, Merck & Co., Inc, Novartis AG, Pfizer, Inc., Qiagen and Sanofi.

Key Developments:

In November 2023, The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

In November 2023, Amgen announced new data reinforcing the safety and efficacy of Repatha® (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia. These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL "bad" cholesterol (LDL-C). Amgen will also present new research from the Phase 2 OCEAN(a)-DOSE study of its investigational small interfering RNA (siRNA) olpasiran that will focus on a primarily genetically determined and presumed independent CVD risk factor, lipoprotein(a) [Lp(a)].

In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.

Cancer Types Covered:

• Acral Lentiginous Melanoma
• Amelanotic Melanoma
• Lentigno gna Melanoma
• Nodular Melanoma
• Superficial Spreading Melanoma
• Other Cancer Types

Diagnosis Covered:

• Dermatoscopy
• Blood Tests
• Computed Tomography (CT) Scan
• Sentinel Lymph Node Biopsy
• Ultrasound
• X-Rays
• Other Diagnosis

Therapies Covered:

• Chemotherapy
• Biological Therapy
• Immune Therapy
• Radiotherapy
• Targeted Therapy
• Other Therapies

Applications Covered:

• Diagnostic Centers
• Hospitals
• Medical Institutions
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances